Alfa Wassermann and Norgine get EU approval for Xifaxan
Italy-based Alfa Wassermann and Netherlands-headquartered Norgine say they have received European Marketing Authorization for Xifaxan 550mg (rifaximin-alpha) - also trade-named Refero, Targaxan and Ticteller - in the reduction of recurrence of episodes of overt hepatic encephalopathy (HE) in patients ≥ 18 years of age, in a number of European Union territories. First launches in Europe are expected in the first half of 2013.
Rifaximin-alpha, developed by Alfa Wassermann, is currently marketed in many countries worldwide, including the USA in a number of indications. A pivotal trial by Bass and colleagues (2010) demonstrated the efficacy of twice-daily (bid) treatment with Xifaxan 550mg in patients with HE.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze